JP2023533982A5 - - Google Patents

Info

Publication number
JP2023533982A5
JP2023533982A5 JP2023501137A JP2023501137A JP2023533982A5 JP 2023533982 A5 JP2023533982 A5 JP 2023533982A5 JP 2023501137 A JP2023501137 A JP 2023501137A JP 2023501137 A JP2023501137 A JP 2023501137A JP 2023533982 A5 JP2023533982 A5 JP 2023533982A5
Authority
JP
Japan
Prior art keywords
alkyl
pharmaceutically acceptable
acceptable salt
heteroaryl
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023501137A
Other languages
English (en)
Japanese (ja)
Other versions
JP7758369B2 (ja
JP2023533982A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/015263 external-priority patent/WO2022010537A1/en
Publication of JP2023533982A publication Critical patent/JP2023533982A/ja
Publication of JP2023533982A5 publication Critical patent/JP2023533982A5/ja
Application granted granted Critical
Publication of JP7758369B2 publication Critical patent/JP7758369B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023501137A 2020-07-10 2021-01-27 Gas41阻害剤及びその使用方法 Active JP7758369B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063050303P 2020-07-10 2020-07-10
US63/050,303 2020-07-10
PCT/US2021/015263 WO2022010537A1 (en) 2020-07-10 2021-01-27 Gas41 inhibitors and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2023533982A JP2023533982A (ja) 2023-08-07
JP2023533982A5 true JP2023533982A5 (https=) 2024-02-02
JP7758369B2 JP7758369B2 (ja) 2025-10-22

Family

ID=79291969

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023501137A Active JP7758369B2 (ja) 2020-07-10 2021-01-27 Gas41阻害剤及びその使用方法

Country Status (7)

Country Link
US (1) US11858925B2 (https=)
EP (1) EP4178571A4 (https=)
JP (1) JP7758369B2 (https=)
CN (1) CN116113406B (https=)
AU (1) AU2021304826A1 (https=)
CA (1) CA3185209A1 (https=)
WO (1) WO2022010537A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115974864B (zh) * 2022-12-29 2025-09-16 苏州汉德创宏生化科技有限公司 一种2-(3-氮杂环丁基)噻唑盐的合成方法
CN116143763B (zh) * 2023-03-01 2025-09-23 清华大学 靶向gas41的化合物、gas41抑制剂和药物组合物及其用途
CN119307620A (zh) * 2024-12-19 2025-01-14 上海交通大学医学院附属上海儿童医学中心 预后标志物H4K5la在神经母细胞瘤预后评估中的应用

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3598122A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3993073A (en) 1969-04-01 1976-11-23 Alza Corporation Novel drug delivery device
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US4069307A (en) 1970-10-01 1978-01-17 Alza Corporation Drug-delivery device comprising certain polymeric materials for controlled release of drug
US3731683A (en) 1971-06-04 1973-05-08 Alza Corp Bandage for the controlled metering of topical drugs to the skin
US3996934A (en) 1971-08-09 1976-12-14 Alza Corporation Medical bandage
US3742951A (en) 1971-08-09 1973-07-03 Alza Corp Bandage for controlled release of vasodilators
BE795384A (fr) 1972-02-14 1973-08-13 Ici Ltd Pansements
US3921636A (en) 1973-01-15 1975-11-25 Alza Corp Novel drug delivery device
US3993072A (en) 1974-08-28 1976-11-23 Alza Corporation Microporous drug delivery device
US4151273A (en) 1974-10-31 1979-04-24 The Regents Of The University Of California Increasing the absorption rate of insoluble drugs
US3972995A (en) 1975-04-14 1976-08-03 American Home Products Corporation Dosage form
US4077407A (en) 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4031894A (en) 1975-12-08 1977-06-28 Alza Corporation Bandage for transdermally administering scopolamine to prevent nausea
US4060084A (en) 1976-09-07 1977-11-29 Alza Corporation Method and therapeutic system for providing chemotherapy transdermally
US4201211A (en) 1977-07-12 1980-05-06 Alza Corporation Therapeutic system for administering clonidine transdermally
JPS5562012A (en) 1978-11-06 1980-05-10 Teijin Ltd Slow-releasing preparation
US4230105A (en) 1978-11-13 1980-10-28 Merck & Co., Inc. Transdermal delivery of drugs
US4229447A (en) 1979-06-04 1980-10-21 American Home Products Corporation Intraoral methods of using benzodiazepines
CA1146866A (en) 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
US4291015A (en) 1979-08-14 1981-09-22 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing a vasodilator
US5116817A (en) 1982-12-10 1992-05-26 Syntex (U.S.A.) Inc. LHRH preparations for intranasal administration
US4476116A (en) 1982-12-10 1984-10-09 Syntex (U.S.A.) Inc. Polypeptides/chelating agent nasal compositions having enhanced peptide absorption
US4596795A (en) 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
US4755386A (en) 1986-01-22 1988-07-05 Schering Corporation Buccal formulation
US5312325A (en) 1987-05-28 1994-05-17 Drug Delivery Systems Inc Pulsating transdermal drug delivery system
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
US5739136A (en) 1989-10-17 1998-04-14 Ellinwood, Jr.; Everett H. Intraoral dosing method of administering medicaments
US5633009A (en) 1990-11-28 1997-05-27 Sano Corporation Transdermal administration of azapirones
WO1992018106A1 (fr) 1991-04-16 1992-10-29 Nippon Shinyaku Co., Ltd. Procede de production d'une dispersion solide
US5340591A (en) 1992-01-24 1994-08-23 Fujisawa Pharmaceutical Co., Ltd. Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
US5281420A (en) 1992-05-19 1994-01-25 The Procter & Gamble Company Solid dispersion compositions of tebufelone
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
AU4198793A (en) 1992-07-24 1994-01-27 Takeda Chemical Industries Ltd. Microparticle preparation and production thereof
US5700485A (en) 1992-09-10 1997-12-23 Children's Medical Center Corporation Prolonged nerve blockade by the combination of local anesthetic and glucocorticoid
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
JP2825755B2 (ja) * 1993-04-07 1998-11-18 大塚製薬株式会社 ピペリジン誘導体を有効成分とする末梢血管拡張剤および新規ピペリジン誘導体
US5656642A (en) 1993-04-07 1997-08-12 Otsuka Pharmaceutical Co., Ltd. Peripheral vasodilating agent containing piperidine derivative as active ingredient
US5665378A (en) 1994-09-30 1997-09-09 Davis; Roosevelt Transdermal therapeutic formulation
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
ES2153031T4 (es) 1995-04-20 2001-05-16 Pfizer Derivados del acido arilsulfonil hidroxamico como inhibidores de mmp y tnf.
SE9502244D0 (sv) 1995-06-20 1995-06-20 Bioglan Ab A composition and a process for the preparation thereof
ATE225343T1 (de) 1995-12-20 2002-10-15 Hoffmann La Roche Matrix-metalloprotease inhibitoren
US5858401A (en) 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
US6923983B2 (en) 1996-02-19 2005-08-02 Acrux Dds Pty Ltd Transdermal delivery of hormones
US6929801B2 (en) 1996-02-19 2005-08-16 Acrux Dds Pty Ltd Transdermal delivery of antiparkinson agents
EP0818442A3 (en) 1996-07-12 1998-12-30 Pfizer Inc. Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor
KR20000067904A (ko) 1996-07-18 2000-11-25 디. 제이. 우드, 스피겔 알렌 제이 매트릭스 메탈로프로테아제의 포스피네이트계 억제제
KR20000068248A (ko) 1996-08-23 2000-11-25 디. 제이. 우드, 스피겔 알렌 제이 아릴설포닐아미노 하이드록삼산 유도체
JP3338064B2 (ja) 1997-01-06 2002-10-28 ファイザー・インク 環状スルホン誘導体
US6458373B1 (en) 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
NZ336840A (en) 1997-02-03 2001-01-26 Pfizer Prod Inc Arylsulfonylamino hydroxamic acid derivatives useful in the treatment of tumor necrosis factor and matrix metalloproteinase mediated diseases
JP2000507975A (ja) 1997-02-07 2000-06-27 ファイザー・インク N−ヒドロキシ−β−スルホニルプロピオンアミド誘導体類及びそれらのマトリックスメタロプロテイナーゼ阻害薬としての使用
EP0960098A1 (en) 1997-02-11 1999-12-01 Pfizer Inc. Arylsulfonyl hydroxamic acid derivatives
US6391452B1 (en) 1997-07-18 2002-05-21 Bayer Corporation Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations
CA2299355C (en) 1997-08-08 2005-09-27 Pfizer Products Inc. Aryloxyarylsulfonylamino hydroxamic acid derivatives
GB9725782D0 (en) 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents
US5869090A (en) 1998-01-20 1999-02-09 Rosenbaum; Jerry Transdermal delivery of dehydroepiandrosterone
GB9801690D0 (en) 1998-01-27 1998-03-25 Pfizer Ltd Therapeutic agents
PA8469501A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
PA8469401A1 (es) 1998-04-10 2000-05-24 Pfizer Prod Inc Derivados biciclicos del acido hidroxamico
US6946144B1 (en) 1998-07-08 2005-09-20 Oryxe Transdermal delivery system
EP1004578B1 (en) 1998-11-05 2004-02-25 Pfizer Products Inc. 5-oxo-pyrrolidine-2-carboxylic acid hydroxamide derivatives
ATE400252T1 (de) 1999-02-10 2008-07-15 Pfizer Prod Inc Pharmazeutische feste dispersionen
CA2374947A1 (en) 1999-05-24 2000-11-30 Robert M. Scarborough Inhibitors of factor xa
GB9912961D0 (en) 1999-06-03 1999-08-04 Pfizer Ltd Metalloprotease inhibitors
EP1081137A1 (en) 1999-08-12 2001-03-07 Pfizer Products Inc. Selective inhibitors of aggrecanase in osteoarthritis treatment
IL149701A0 (en) 2001-05-23 2002-11-10 Pfizer Prod Inc Use of anti-ctla-4 antibodies
US6960563B2 (en) 2001-08-31 2005-11-01 Morton Grove Pharmaceuticals, Inc. Spontaneous emulsions containing cyclosporine
FR2856685B1 (fr) * 2003-06-25 2005-09-23 Merck Sante Sas Derives de thiazolylpiperidine, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
KR20080095915A (ko) 2004-05-06 2008-10-29 워너-램버트 캄파니 엘엘씨 4-페닐아미노-퀴나졸린-6-일-아미드
SG172738A1 (en) * 2005-07-29 2011-07-28 4Sc Ag Novel heterocyclic nf-kb inhibitors
CN101287728A (zh) * 2005-08-17 2008-10-15 先灵公司 新的高亲和力噻吩基和呋喃基激酶配体
BRPI0620362A2 (pt) * 2005-12-22 2012-07-03 Astrazeneca Ab composto ou um sal farmaceuticamente aceitável do mesmo, uso do mesmo, métodos para produzir um efeito inibidor de csf-1r quinase em um animal de sangue quente, para produzir um efeito anti-cáncer em um animal de sangue quente e para tratar doença, e, composição farmacêutica
US8017612B2 (en) * 2006-04-18 2011-09-13 Japan Tobacco Inc. Piperazine compound and use thereof as a HCV polymerase inhibitor
CA2690557A1 (en) * 2007-06-14 2008-12-24 Schering Corporation Imidazopyrazines as protein kinase inhibitors
AU2009203549B2 (en) * 2008-01-08 2013-03-07 Purdue Pharma L.P. Proline Analogs as ligands for cannabinoid receptors for the treatment of pain
EP4166558A1 (en) 2010-02-12 2023-04-19 Pfizer Inc. Salts and polymorphs of 8-fluoro-2-{4- [(methylamino)methyl]phenyl}-1 ,3,4,5-tetrahydro-6h-azepino[5,4,3- cd]indol-6-one
EP2781521A4 (en) * 2011-10-19 2015-03-04 Kowa Co NEW SPIROINDOLIN COMPOUND AND MEDICAL AGENT THEREFOR
CN102416183B (zh) * 2011-12-06 2013-04-17 厦门大学 miR-297b的用途
US10259824B2 (en) * 2015-05-01 2019-04-16 The Regents Of The University Of California Complement C3d-binding compounds
EP3404021A4 (en) * 2016-01-12 2019-09-11 Nippon Chemiphar Co., Ltd. VOLTAGE-RELATED T-TYPE CALCIUM CHANNEL INHIBITOR
JP7178401B2 (ja) * 2017-07-11 2022-11-25 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ コリンキナーゼ阻害剤としてのピラゾロキナゾリン誘導体
EP3717504A4 (en) * 2017-11-27 2021-10-20 The University of Hong Kong YEATS INHIBITORS AND METHOD OF USING
EP3813819A4 (en) * 2018-06-29 2022-08-17 Kinnate Biopharma Inc. CYCLIN-DEPENDENT KINASE INHIBITORS

Similar Documents

Publication Publication Date Title
RU2009115784A (ru) Производные пиразоло[1,5-а]пиримидина и их применение в медицине
JP2023533982A5 (https=)
JP2005538100A5 (https=)
RU2336275C2 (ru) Пиримидопроизводные, характеризующиеся антипролиферативной активностью, и фармацевтическая композиция
RU2375363C2 (ru) Пирролотриазиновые производные анилина, полезные в качестве ингибиторов киназы
JP2005535586A5 (https=)
JP2022506887A5 (https=)
JP2008528467A5 (https=)
RU2002125860A (ru) Новые производные циклического амида
RU2007139453A (ru) Гетеробициклические ингибиторы вируса гепатита с (hcv)
JP2020511454A5 (https=)
JP2006515858A5 (https=)
RU2006112593A (ru) Производные 2, 4-ди(гетеро)ариламинопиримидина в качестве ингибиторов zap-70 и/или syk
JP2021075570A5 (https=)
ZA200508158B (en) Derivatives of piperidinyl- and piperazinyl-alkyl carbamates, preparation methods thereof and application of same in therapeutics
RU2008136187A (ru) Новое производное кумарина, обладающее противоопухолевой активностью
JP2005511531A5 (https=)
RU2003117476A (ru) Аминотиазолы и их применение в качестве антагонистов рецептора аденозина
JP2022526266A5 (https=)
JP2006517220A5 (https=)
RU2003115429A (ru) Производные имида индолилмалеиновой кислоты как ингибиторы протеинкиназы с
JP2007524696A5 (https=)
JP2006524673A5 (https=)
RU2014153627A (ru) Имидазо[1, 2-]пиридазиновые производные как ингибиторы киназ
JP2005537323A5 (https=)